Medical marijuana stocks have been all the rage and CARA has been lumped into that category, but the story is much deeper. Dr. Derek Chalmer, CEO of Cara Therapeutics joins Jill Malandrino at the NASDAQ MarketSite to give a complete review of the company. The company’s lead program is an opiate-based program with the promise of analgesia with no narcotic side effects. CARA’s main focus is obtaining approval for the first medications for 2016.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
